A Phase IB/III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib Versus Placebo and Ruxolitinib in Patients With Intermediate- or High-Risk Myelofibrosis
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Vismodegib (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Roche
- 23 Nov 2017 Status changed from recruiting to discontinued.
- 26 Jul 2017 Planned End Date changed from 1 Nov 2019 to 13 Dec 2019.
- 26 Jul 2017 Planned primary completion date changed from 1 Nov 2019 to 13 Dec 2019.